Biovaxys Technology CorpOTCQB:BVAXFView on Canadian Exchange
- LAST PRICE0.0449
- TODAY'S CHANGE (%)-0.0006 (-1.3187%)
- Bid / Lots0.0406/ 690
- Ask / Lots0.0500/ 996
- Open / Previous Close0.0428 / 0.0455
- Day Range
- 52 Week Range
- Volume87,500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BVAXF |
|---|---|---|
| 09:34 ET | 55000 | 0.0448 |
| 09:39 ET | 5000 | 0.04605 |
| 09:56 ET | 10000 | 0.04619 |
| 10:03 ET | 7500 | 0.043265 |
| 10:06 ET | 7500 | 0.0449 |
Today
Yesterday
BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT, from 15 hours ago by Dow Jones
15 hours ago by Dow Jones
Sep 4, 2024
BioVaxys to Present New Data on its DPX Immune Educating Platform at Personalized Cancer Vaccine Summit, from 7:00AM ET on Wednesday Sep 04, 2024 by Dow Jones
7:00AM ET on Wednesday Sep 04, 2024 by Dow Jones
Aug 22, 2024
BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases, from 8:33AM ET on Thursday Aug 22, 2024 by Dow Jones
8:33AM ET on Thursday Aug 22, 2024 by Dow Jones
Aug 19, 2024
SPAYVAC FOR WILDLIFE, INC. ANNOUNCES COMPLETION OF SPAYVAC RESEARCH AND PRODUCTION FACILITY IN MADISON, WISCONSIN, from 8:00AM ET on Monday Aug 19, 2024 by Dow Jones
8:00AM ET on Monday Aug 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Biovaxys Technology Corp | 14.8M | --- | --- |
Company Information
BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.
Contact Information
- Headquarters
- 146 Thirtieth Street, Suite 100TORONTO, ON, Canada M8W 3D4
- Phone
- 604-262-8835
- Fax
- 604-262-8835
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 246.9M |
Biovaxys Technology Corp does not pay a dividend. | |
Beta | 3.52 |
EPS | $-0.04 |
Book Value | $-0.02 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
